ReviewExpert opinion on biological therapy2009
Novel HIV-1 therapeutics through targeting altered host cell pathways.
Review in Expert opinion on biological therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- HIV-1-related factors interact with p53 to influence cellular processes.AIDS research and therapy · 2023Review
- Review
- The Road Less Traveled: HIV's Use of Alternative Routes through Cellular Pathways.Journal of virology · 2015Review
- HIV-1 and morphine regulation of autophagy in microglia: limited interactions in the context of HIV-1 infection and opioid abuse.Journal of virology · 2015Article
- Targeting HIV transcription: the quest for a functional cure.Current topics in microbiology and immunology · 2015Review
- Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation.Advances in virology · 2015Article
- Structural insights of non-canonical U*U pair and Hoogsteen interaction probed with Se atom.Nucleic acids research · 2013Article
- Article
- Article
- Article
- Review
- Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors.Virology journal · 2012Article
- Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways.PloS one · 2012Article
- The human transcriptome during nontyphoid Salmonella and HIV coinfection reveals attenuated NFkappaB-mediated inflammation and persistent cell cycle disruption.The Journal of infectious diseases · 2011Article
- HIV-1 replication and latency are regulated by translational control of cyclin T1.Journal of molecular biology · 2011Article
- Cyclin E goes nuts: a cell cycle regulator affects male fertility.Cell cycle (Georgetown, Tex.) · 2010Article
- The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.AIDS research and therapy · 2010Article
- Cellular networks involved in the influenza virus life cycle.Cell host & microbe · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The emergence of drug-resistant HIV-1 strains presents a challenge for the design of new drugs. Anti-HIV compounds currently in use are the subject of advanced clinical trials using either HIV-1 reverse transcriptase, viral protease or integrase inhibitors. Recent studies show an increase in the number of HIV-1 variants resistant to anti-retroviral agents in newly infected individuals. Targeting host cell factors involved in the regulation of HIV-1 replication might be one way to combat HIV-1 resistance to the currently available anti-viral agents. A specific inhibition of HIV-1 gene expression could be expected from the development of compounds targeting host cell factors that participate in the activation of the HIV-1 LTR promoter. Here we discuss how targeting the host can be accomplished either by using small molecules to alter the function of the host's proteins such as p53 or cdk9, or by utilizing new advances in siRNA therapies to knock down essential host factors such as CCR5 and CXCR4. Finally, we will discuss how the viral protein interactomes should be used to better design therapeutics against HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.